Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release

Archives of General Psychiatry

Volumn 67, Issue 12, 2010, Pages 1274-1281

  Rickels, Karl ^a   Etemad, Bijan ^a   Khalid Khan, Sarosh ^a   Lohoff, Falk W ^a   Rynn, Moira A ^a   Gallop, Robert J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG RELEASE; FAINTNESS; FATIGUE; FEMALE; FLATULENCE; GAS; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; LIBIDO; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NERVOUSNESS; NIGHTMARE; ORGASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649952466     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2010.170     Document Type: Article

References (40)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication (published corrrection appears in Arch Gen Psychiatry. 2005;62(7):709). Arch Gen Psychiatry. 2005;62(6):617-627.
2. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70(l2)(suppl 2):4-9.
3. Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry. 2002;63(8)(suppl 8):11-16. (Pubitemid 34535252)
4. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156(12):1915-1923.
5. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA. 1994;272(22):1741-1748.
6. Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, Lubeck DP, Buesching DP. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord. 1997;43(2):105-119.
7. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000;15(6):319-328.
8. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(10):1205-1215. (Pubitemid 41546498)
9. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171.
10. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328(19):1398-1405.
11. Rickels K, Csanalosi I, Greisman P, Cohen D, Werblowsky J, Ross HA, Harris H. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry. 1983;140(1):82-85.
12. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43(12, pt 2):81-86.
13. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl). 1991;105(3):428-432.
14. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, Fisher S, Frankenthaler LM. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry. 1986;43(1):79-85.
15. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-895. (Pubitemid 23330980)
16. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157(6):968-974.
17. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008-2014.
18. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(4):749-756. (Pubitemid 41079609)
19. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009;70(suppl 2):25-31.
20. Rickels K, Case WG, Downing RW, Fridman R. One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol. 1986;6(1):32-36.
21. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996;168(3):308-313.
22. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA. 1983;250(6):767-771.
23. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45(5):444-450.
24. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082-3088.
25. Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2005;66(11):1441-1446. (Pubitemid 41779543)
26. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK; Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250-258.
27. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(5):495-505.
28. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673-681.
29. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Revised. Rockville, MD: National Institute of Mental Health; 1976. DHEW publication (ADM) 76-338.
30. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370.
31. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.
32. Bech P. Rating Scales for Psychopathology, Health Status and Quality of Life. New York, NY: Springer-Verlag; 1993:402-404.
33. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(suppl 22):29-34.
34. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154(12):1760-1762.
35. Willett JB, Singer JD. Investigating onset, cessation, relapse, and recovery: why you should, and how you can, use discrete-time survival analysis to examine event occurrence. J Consult Clin Psychol. 1993;61(6):952-965.
36. Collett D. Modelling Survival Data in Medical Research. 2nd ed. New York, NY: Chapman & Hall; 1994.
37. Verbeke G, Molenberghs G, eds. Linear Mixed Model for Longitudinal Data. New York, NY: Springer-Verlag; 2000.
38. Little RJ. Modelling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc. 1995;90(431):1112-1121.
39. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;3(1):64-78.
40. Guo W, Ratcliffe SJ, Ten Have TR. A random pattern-mixture model for longitudinal data with dropouts. J Am Stat Assoc. 2004;99(468):929-937.